Investing.com -- Septerna Inc (NASDAQ:SEPN) stock surged 21% Friday after Wells Fargo analyst Derek Archila upgraded the company from Equal Weight to Overweight with a price target of $28.00.
The significant price target represents approximately 46% upside from Thursday’s closing price of $19.24. Archila’s upgrade follows investor meetings with Septerna management, where the analyst "gained confidence" on SEP-479’s safety profile and its "differentiation" compared to the company’s prior program.
Wells Fargo identified two key upcoming catalysts that could drive further momentum for the stock: SEP-479’s advancement into Phase 1 clinical trials and an update on SEP-631’s Phase 1 progress, both expected in the first half of 2026.
The upgrade highlights growing optimism around Septerna’s pipeline development and clinical progress. The company’s shares have responded strongly to the positive analyst assessment, reflecting renewed investor interest in its drug development programs.
Septerna focuses on developing novel therapeutics targeting G protein-coupled receptors (GPCRs), which are involved in various physiological processes and represent important targets for drug development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
